Idenix CEO Renaud has plan to recover from clinical setbacks, company's stock rallies
This article was originally published in Scrip
Idenix Pharmaceuticals CEO Ron Renaud admits his company has had a “tough track record” developing drugs over the past couple of years.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.